The global fill-finish pharmaceutical contract manufacturing market size is expected to reach USD 14.01 billion by 2030. The market is expected to expand at a CAGR of 6.0% over the forecast period, according to a new report by Grand View Research, Inc. The increasing demand for injectable drugs is one of the primary drivers of the fill-finish pharmaceutical contract manufacturing market. Injectable drugs are medications that are delivered directly into the bloodstream, muscle tissue, or other parts of the body using a needle and syringe or other delivery system. These drugs are used to treat a wide range of conditions, including cancer, autoimmune disorders, and infectious diseases, among others.
The demand for injectable drugs has been growing steadily in recent years due to several factors. One of the key drivers is the increasing prevalence of chronic diseases such as cancer and diabetes, which require long-term treatment with injectable medications. Additionally, the development of new biologic drugs, which are often administered via injection, has also contributed to the growing demand for injectable drugs.
The COVID-19 pandemic has had a significant impact on the market. Fill-finish contract manufacturing is an essential part of the pharmaceutical industry, which involves the filling and finishing of drug products into vials, syringes, cartridges, and other delivery systems. The pandemic caused disruptions in the global supply chain, resulting in shortages of raw materials and other critical components required for operations. This has led to delays in the production of drugs and vaccines, particularly those used in the treatment of COVID-19 patients.
Moreover, the pandemic has also caused an increase in demand for certain drugs and vaccines, further straining the capacity of fill-finish contract manufacturers. Many manufacturers have been forced to operate at reduced capacity due to social distancing guidelines and other restrictions imposed to control the spread of the virus.
Request a free sample copy or view report summary: Fill-Finish Pharmaceutical Contract Manufacturing Market Report
The large molecules segment accounted for the largest revenue share of 67.2% in 2022 due to the rising potential to treat unmet medical needs
The vials segment is accounted for the highest revenue share of 52.9% in 2022 due to increasing technological advancements in vial filling equipment
The biopharmaceutical companies segment accounted for the highest revenue share of 54.9% in 2022, an increase in the development of drugs and vaccines is the key factor for the growth of the market
By region, Asia Pacific region dominated the market in 2022 and also expected to witness the fastest CAGR of 6.3% over the forecast period
Grand View Research has segmented the global fill-finish pharmaceutical contract manufacturing market based on product type, molecule type, end-user, and region:
Fill-Finish Pharmaceutical Contract Manufacturing Product Type Outlook (Revenue, USD Million, 2018 - 2030)
Prefilled Syringes
Vials
Cartridges
Others
Fill-Finish Pharmaceutical Contract Manufacturing Molecule Type Outlook (Revenue, USD Million, 2018 - 2030)
Large Molecules
Small Molecules
Fill-Finish Pharmaceutical Contract Manufacturing End-user Outlook (Revenue, USD Million, 2018 - 2030)
Biopharmaceutical Companies
Pharmaceutical Companies
Fill-Finish Pharmaceutical Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Fill-Finish Pharmaceutical Contract Manufacturing Market
AbbVie Inc.
Boehringer Ingelheim
Catalent
Pfizer
Recro Pharma, Inc.
Baxter’s BioPharma Solutions
Eurofins Scientific
Symbiosis Pharmaceutical Service
MabPlex International Co. Ltd.
Recipharm AB
Fresenius Kabi Contract Manufacturing
Novartis
"The quality of research they have done for us has been excellent..."